|
|
 |
|
Viewing report
|
|
|
|
AstraZeneca PLC (AZN) - Financial and Strategic SWOT Analysis Review
GlobalData, April 2012, Pages: 54
AstraZeneca PLC (AZN) - Financial and Strategic SWOT Analysis Review
Summary
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company, carries out designing, developing, production and marketing of various range of biologics, prescription pharmaceuticals and vaccines for the treatment of diseases like cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation. Its research and development activities are focused on the development of implants and medical devices with principle focus on type 2 diabetes, infection, COPD, cancer, Alzheimer's diseases and other areas. The product portfolio of the company includes Crestor, Seroquel, Arimidex, Nexium and Symbicort. Geographically, the company holds its presence in more than 100 countries throughout the world. It has 14 research and development sites in eight countries as well as 23 manufacturing plants located in eight countries. AstraZeneca is headquartered in London, the UK.
The key business strategies of the company include enhanced focus on providing high quality pharmaceutical products that make most meaningful difference to patients health. It mainly aims to create high value to shareholders by maintaining the quality of its product pipeline. It also aims to maintain its existing partnerships and to enter new collaborative agreements to fuel its services. This is indicated by recent partnership and collaboration agreements signed with Guangdong BeiKang Pharmaceutical Company Ltd., which enables the company to enter into China market and obtain access to a portfolio of injectable medicines.
AstraZeneca PLC Key Recent Developments
Feb 08, 2012: AstraZeneca US Broadens Income Eligibility For Prescription Savings Programs
Feb 02, 2012: AstraZeneca Reports Revenue Of $8.7 Billion In Q4 2011
Feb 02, 2012: AstraZeneca Announces New Restructuring Initiatives To Drive Productivity And Support Innovation
Jan 24, 2012: AstraZeneca Donates $3.8m In Medicines For US Free Clinics
Jan 11, 2012: AstraZeneca And IMS Health Announce Real-World Evidence Collaboration In Europe
This comprehensive SWOT profile of AstraZeneca PLC provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Note: Some sections may be missing if data is unavailable for the company.
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Customers who bought this item also bought
GlaxoSmithKline plc (GSK) - Financial and Strategic SWOT Analysis Review
AstraZeneca PLC Market Share Analysis
AstraZeneca plc: PharmaVitae Profile
AstraZeneca AB - Product Pipeline Review - Q4 2010
AstraZeneca PLC - Strategy, SWOT, and Corporate Finance Report
Shire Plc (SHP) - Financial and Strategic SWOT Analysis Review
Ariad Pharmaceuticals, Inc. (ARIA) - Financial and Strategic SWOT Analysis Review
MedImmune, LLC - Strategic SWOT Analysis Review
Covidien plc (COV) - Financial and Strategic SWOT Analysis Review
Vectura Group plc (VEC) - Financial and Strategic SWOT Analysis Review
|
|
|
|
